Modified NK-92 Cells With CD16 and IL-2 for ADCC Therapy

Solution Overview

Problem

NK-92 cells lack the CD16 receptor, preventing them from effectively mediating antibody-dependent cellular cytotoxicity (ADCC) against cancer cells, and require external IL-2 for growth, which can cause adverse side effects.

Innovation Solution

Modified NK-92 cells (haNK003) are engineered to express the CD16 receptor and produce IL-2 intracellularly, enabling ADCC and self-sustenance without external IL-2, with the CD16 receptor being stably integrated and IL-2 targeted to the endoplasmic reticulum.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If NK-92 cells are used as cytotoxic effector cells, then they retain activating receptors and cytolytic pathways, but they lack CD16 receptors and cannot mediate ADCC

Engineering Contradiction:

ImproveADCC capabilityVSAvoidreceptor expression profile

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent introduces an IL-2 gene into NK-92 cells to enable self-sustaining proliferation. The modified cells produce their own growth factor, eliminating the need for external IL-2 supplementation and achieving self-service for maintaining cell population during therapy.

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The patent uses a viral vector as an intermediary to deliver the CD16 gene into NK-92 cells. This mediator enables the transfer and stable expression of the missing CD16 receptor, bridging the gap between the cell's natural state and the desired ADCC-capable state.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If external IL-2 is used to support NK-92 cell growth, then cell proliferation is maintained, but adverse side effects occur

Engineering Contradiction:

Improvecell proliferationVSAvoidadverse side effects

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces an IL-2 gene into NK-92 cells to enable self-sustaining proliferation. The modified cells produce their own growth factor, eliminating the need for external IL-2 supplementation and achieving self-service for maintaining cell population during therapy.

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The patent extracts the IL-2 production function from the external environment and relocates it into the NK-92 cells themselves. This extraction eliminates the need for external IL-2 administration and its associated side effects while maintaining cell proliferation capability.

Inventive Principle:

Principle #2Taking out (Extraction)

3Reliability

If CD16 receptor is added to NK-92 cells to enable ADCC, then cytotoxicity against cancer cells is enhanced, but cell line complexity increases

Engineering Contradiction:

ImproveADCC activityVSAvoidcell line modification

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses a viral vector as an intermediary to deliver the CD16 gene into NK-92 cells. This mediator enables the transfer and stable expression of the missing CD16 receptor, bridging the gap between the cell's natural state and the desired ADCC-capable state.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent employs a viral vector system that can deliver multiple genetic elements (CD16 gene and IL-2 gene) simultaneously, achieving multiple functions (ADCC capability and self-sustaining proliferation) through a single delivery mechanism, thereby managing complexity efficiently.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20260078342A1MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC

Publication Date: 2026.03.19 NANTKWEST INC

AI summary

Provided herein are populations of modified NK-92 cells, compositions and kits comprising the cells, and methods of making and using the populations of cells.